The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
AI is in Every Pharma Strategy Deck
Could a Formal Trust Coefficient Release the Pharmacovigilance Capacity AI Promised
Complex Journey from Innovation to Patient impact
Why Sustainable Biomanufacturing Must Start Earlier in The Process
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
University of Lincoln, UK
Senior Lecturer, School of Pharmacy
Ishwar Singh is a Senior Lecturer in Biological Chemistry at the School of Pharmacy University of Lincoln Prior to Lincoln he had held many prestigious fellowships such as the Alexander von Humboldt fellowship Germany and Senior Research Fellowship DANIDA Denmark and CSIR India He is an organic chemist He has developed bioconjugations for DNA RNA and polymer modifications in water He is currently...
Articles
APAC’s Rising Role in Neurodegenerative Disease Research and Development
Neurodegenerative diseases represent one of the most pressing global health challenges of the coming decades driven by aging populations increasing disease prevalence and the absence of curative therapies While historically concentrated in North America and Europe research and development efforts in this field are increasingly expanding toward the AsiaPacific APAC region reflecting broader shifts...
Research Insights
Functional human genes typically exhibit epigenetic conservation
Recent DepMap CRISPRCas single gene disruptions have identified genes more essential to proliferation in tissue culture It would be valuable to translate these finding with measurements more practical for human tissues Here we show that DepMap essential genes and other literature curated functional
Case Studies
Out-Of-Hours Antibiotic Prescription After Screening With C Reactive Protein: A Randomised Controlled Case Study
Abstract Fever respiratory symptoms and infections are common among children in primary care especially at outofhours OOH services Serious infections have low prevalence in primary care and even more so after introduction of vaccines for Haemophilus influenzae type B and pneumococcal conjugate vaccines It is challenging for clinicians to distinguish se
Techno Trends
Newly Engineered Cas9 Now Allows Isolated Gene-editing
Genetic engineers and researchers alike have explicitly shared their affinity towards the geneediting tool called CRISPRCas This device alters targeted genes effortlessly thereby permitting an executable approach to developing treatments and cures There is however a major limitation to Cas in terms of rectifying an isolated DNA letter in a gene
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
How the Pharmaceutical Industry is Embracing a Technology-Driven Approach to Unlock New Growth Avenues
Nikkhil K Masurkar, a research pharmacist with a dynamic entrepreneurial streak. Nikkhil K Masurkar is executive director of the ENTOD International Group - a leading specialty research-based pharma company specialising in ophthalmic, ENT and Dermatology medicines. As a third generation entrepreneur, Nikkhil took over his family’s three decade old pharmaceutical business. However, to ensure he was adequately prepared to lead the organisation into the 21st century, he delved deep into clinical pharmacy and pharmacy research for several years prior to it. He is a highly qualified research pharmacist from Kings College London (UK) with various clinical pharmacy and formulation research accreditations to his name. He also studied clinical pharmacy in Belfast and is also a member of the prestigious Royal Pharmaceutical Society in the UK. His strong leadership qualities, dynamic entrepreneurial spirit and sharp business acumen together with impressive pharmaceutical and research skills have enabled ENTOD to become one of the fastest growing speciality pharmaceutical companies in India and abroad.
How Ready are Cellulose Nanocrystals in Delivery of Anticanceragents?
Researcher, Donghua University
Demystifying Lead-time bias and Length-time bias in Clinical Trials
Jefry Winner G has completed his MBBS from Vinayaka Missions Medical College. He is currently pursuing a Doctorate of Medicine in Pharmacology at JIPMER Puducherry. He is interested in clinical research and is currently involved in an academic clinical trial involving Epilepsy. He has four years of clinical experience in healthcare and Academia. His area of interest includes Clinical trials, Pharmacotherapeutics, Drug safety, and clinical pharmacology. He also has over 15 publications in peer-reviewed journals.
Kinase Inhibitors as Antiviral Agents
Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.
Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.
Meet scientist Daria Donati
Daria’s work is ongoing. Her role at Cytiva involves identifying new and innovative technologies that can help in the development of therapeutics. This means building partnerships, improving manufacturing processes and, ultimately, getting life- saving drugs to the people who need them most.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
